Bial R&D Investments, S.A.
3 clinical trials · Sponsor
◉ Watch Bial R&D Investments, S.A.
| Record | Firm | Date |
|---|---|---|
| Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD (NCT05819359) | Bial R&D Investments, S.A. | 2023-03-31 |
| Mass Balance Recovery and Metabolite Identification of Carbon-14 BIA 28-6156 (NCT05220072) | Bial R&D Investments, S.A. | 2021-08-28 |
| Compassionate Use for BIA 28-6156 in Patients With Parkinson's Disease (PD) Who Have a Pathogenic Variant in the GBA1 Gene (GBA-PD) and Completed the ACTIVATE Study (NCT07522606) | Bial R&D Investments, S.A. |
Track Bial R&D Investments, S.A. automatically
Every clearance here is in the API, with alerts when new ones post.